公开(公告)号：US12011535B2

公开(公告)日：2024-06-18

申请号：US18072656

申请日：2022-11-30

申请人： QNOVIA, INC.

发明人： Mario Danek ,  Ian Kovacevich ,  Andrew Heinrich ,  Christopher Kar-Heng Cheng ,  Joseph Gene Walsh

IPC分类号： A24F40/10 ,  A24B15/167 ,  A24F40/05 ,  A24F40/42 ,  A61K9/00 ,  A61K9/107 ,  A61K9/127 ,  A61K31/00 ,  A61K31/05 ,  A61K31/352 ,  A61K31/4439 ,  A61K31/465 ,  A61K47/02 ,  A61K47/26 ,  A61M11/00 ,  B05B17/06

CPC分类号： A61M11/003 ,  A24B15/167 ,  A24F40/05 ,  A24F40/10 ,  A24F40/42 ,  A61K9/0078 ,  A61K9/1075 ,  A61K9/127 ,  A61K31/05 ,  A61K31/352 ,  A61K31/4439 ,  A61K31/465 ,  A61K31/658 ,  A61K47/02 ,  A61K47/26 ,  B05B17/0653 ,  A61M2205/0294 ,  A61M2205/12 ,  A61M2205/587 ,  A61M2205/8206

摘要： An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device for delivery of a substance into a body through respiration includes a liquid container; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes a plurality of nanoparticles in a nanoemulsion, the nanoparticles including the encapsulation of the substance to be delivered into the body through respiration. The nanoemulsion preferably is produced using a microfluidizing machine.

公开(公告)号：US12011509B2

公开(公告)日：2024-06-18

申请号：US17509478

申请日：2021-10-25

申请人： Tree of Knowledge International Corp.

发明人： Anshuman Jakhmola ,  Jahangir Tavakkoli ,  Kevin Rod

IPC分类号： A61K9/51 ,  A61K31/05 ,  A61K31/353 ,  B01D21/26

CPC分类号： A61K9/5192 ,  A61K9/5115 ,  A61K9/513 ,  A61K31/05 ,  A61K31/353 ,  B01D21/262

摘要： The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration.

公开(公告)号：US12011422B2

公开(公告)日：2024-06-18

申请号：US17826770

申请日：2022-05-27

申请人： McMaster University

发明人： Eric Brown ,  Omar M Elhalfawy ,  Nick Jentsch ,  Xiong Zhang ,  Jakob Magolan

IPC分类号： A61K31/055 ,  A61K31/05 ,  A61K31/11 ,  A61K31/121 ,  A61K31/341 ,  A61K31/381 ,  A61K31/42 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/505 ,  A61K38/12 ,  A61P31/04 ,  C07C39/19 ,  C07C43/275 ,  C07C49/78 ,  C07C205/18 ,  C07D213/30 ,  C07D215/14 ,  C07D239/26 ,  C07D239/42 ,  C07D261/08 ,  C07D307/48 ,  C07D333/38

CPC分类号： A61K31/055 ,  A61K31/05 ,  A61K31/11 ,  A61K31/121 ,  A61K31/341 ,  A61K31/381 ,  A61K31/42 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/505 ,  A61K38/12 ,  A61P31/04 ,  C07C39/19 ,  C07C43/275 ,  C07C49/78 ,  C07C205/18 ,  C07D213/30 ,  C07D215/14 ,  C07D239/26 ,  C07D239/42 ,  C07D261/08 ,  C07D307/48 ,  C07D333/38

摘要： Provided herein are novel synthetic compounds having the structure of formula (1),




wherein X is a substituted or unsubstituted aromatic or heteroaromatic mono- or polycyclic ring system; and Y is substituted or unsubstituted C5-C10 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium.

公开(公告)号：US12011421B2

公开(公告)日：2024-06-18

申请号：US17521674

申请日：2021-11-08

申请人： Cava Healthcare Inc.

发明人： Wilfred Jefferies ,  Reinhard Gabathuler ,  Raymond Andersen ,  Lilian Nohara ,  David Williams

IPC分类号： A61K31/045 ,  A61K31/05 ,  A61K31/12 ,  A61K45/06 ,  A61N5/10

CPC分类号： A61K31/045 ,  A61K31/05 ,  A61K31/12 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00

摘要： Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

公开(公告)号：US20240189273A1

公开(公告)日：2024-06-13

申请号：US18584338

申请日：2024-02-22

申请人： Zyus Life Sciences Inc.

发明人： Mahsa ABRISHAMI ,  Landon K. PASTUSHOK

IPC分类号： A61K31/352 ,  A61K31/05 ,  A61P29/00

CPC分类号： A61K31/352 ,  A61K31/05 ,  A61P29/00

摘要： A method of opioid replacement is described which involves modulating the expression of dopaminergic genes (such as DRD2), as indicative of substance use disorders in individuals utilizing opioids and desirous of opioid replacement. Opioid replacement can involve a decrease in opioid seeking behavior of the subject, who may require pain management. A cannabinoid formulation is described comprising primarily cannabichromene (CBC) together with an excipient. A method is described for detecting the correlation between CBC treatment and downregulation of biomarkers of DRD2 gene expression. An effective non-psychoactive pain management therapy for opioid replacement is provided, as validated based on the gene expression profile of patients, where patient response to cannabichromene treatment can be predicted by such biomarkers. Such a therapy has the potential to reverse the transcriptional profile of DRD2 through tapering of opioid-induced upregulation, and/or through the potential downregulation of DRD2 expression.

公开(公告)号：US11998514B2

公开(公告)日：2024-06-04

申请号：US17324720

申请日：2021-05-19

申请人： ELEMENTIS SPECIALTIES, INC.

发明人： Joseph Anthony Lupia ,  Kimberly Burch ,  Wouter Ijdo

IPC分类号： A61K9/107 ,  A61K9/06 ,  A61K31/05 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K36/16 ,  A61K36/185 ,  A61K36/258 ,  A61K36/28 ,  A61K36/42 ,  A61K36/53 ,  A61K36/82 ,  A61K36/886 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/22 ,  A61K47/44

CPC分类号： A61K31/05 ,  A61K9/06 ,  A61K9/107 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K36/16 ,  A61K36/185 ,  A61K36/258 ,  A61K36/28 ,  A61K36/42 ,  A61K36/53 ,  A61K36/82 ,  A61K36/886 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/186 ,  A61K47/22 ,  A61K47/44

摘要： A cannabidiol (CBD) gelled delivery system comprising: a rheology modifier; an emollient; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. A CBD emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. For such delivery systems, the cannabidiols contain less than 0.3 wt. % of tetrahydrocannabinol (THC) or the cannabidiols are substantially free of THC. An active gelled delivery system a rheology modifier; an emollient; and one or more actives. An active emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more actives.

公开(公告)号：US20240169856A1

公开(公告)日：2024-05-23

申请号：US18214706

申请日：2023-06-27

申请人： Ojai Energetics PBC

发明人： William KLEIDON

IPC分类号： G09B9/00 ,  A61K9/50 ,  A61K31/05 ,  A61K31/57 ,  A61K36/185 ,  G06F3/01

CPC分类号： G09B9/00 ,  A61K9/50 ,  A61K31/05 ,  A61K31/57 ,  A61K36/185 ,  G06F3/011

摘要： The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

公开(公告)号：US20240165047A1

公开(公告)日：2024-05-23

申请号：US18282410

申请日：2022-08-11

申请人： Chengdu Jinrui Foundation Biotech Co., Ltd.

发明人： Wenbin Li ,  Ce Wang ,  Xintian Lai ,  Xiaobo Wang

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/127 ,  A61P35/00

CPC分类号： A61K31/05 ,  A61K9/0019 ,  A61K9/127 ,  A61P35/00

摘要： The present invention relates to a medical use of honokiol, and in particular to a use of honokiol in the preparation of a drug for treating a meningioma. Experiments prove that honokiol can effectively inhibit the growth of a meningioma, and eliminate and/or reduce lesions of the meningioma. Moreover, clinical experiments show that the safety and tolerance of honokiol are good.

公开(公告)号：US20240164410A1

公开(公告)日：2024-05-23

申请号：US18552070

申请日：2022-03-25

申请人： BrainLuxury Inc.

发明人： Axel Bouchon ,  Herman Schützinger

IPC分类号： A23L2/06 ,  A23L2/52 ,  A61K9/00 ,  A61K9/107 ,  A61K31/05 ,  A61K31/198 ,  A61K31/201 ,  A61K31/355 ,  A61K31/375 ,  A61K31/381 ,  A61K31/405 ,  A61K31/593 ,  A61K33/06 ,  A61K36/02 ,  A61K36/55 ,  A61K36/889 ,  A61P25/26

CPC分类号： A23L2/06 ,  A23L2/52 ,  A61K9/0095 ,  A61K9/107 ,  A61K31/05 ,  A61K31/198 ,  A61K31/201 ,  A61K31/355 ,  A61K31/375 ,  A61K31/381 ,  A61K31/405 ,  A61K31/593 ,  A61K33/06 ,  A61K36/02 ,  A61K36/55 ,  A61K36/889 ,  A61P25/26

摘要： The disclosure is in part directed to shelf-stable, emulsion-forming liquid compositions, liquid beverage compositions, and fatty acid vesicle-forming liquid compositions for increased neurosystem uptake of amino acids present in the compositions when consumed by a subject.

公开(公告)号：US20240156843A1

公开(公告)日：2024-05-16

申请号：US18416953

申请日：2024-01-19

申请人： ECP Pharma

发明人： Nitin ANAND ,  Michael E. HOFFER ,  Moiz RANGWALLA ,  Andy MERA ,  Gilberto IRAGORRI

IPC分类号： A61K31/675 ,  A61K31/05 ,  A61P25/28

CPC分类号： A61K31/675 ,  A61K31/05 ,  A61P25/28

摘要： The disclosure relates to methods for treating brain injuries that include administering to a patient a first dosage of about 100 mg to about 500 mg of cannabidiol (CBD) and administering to the patient, concomitantly with the first dosage, a second dosage of about 1 to about 10 milligrams of Psilocybin.